Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti-seizure efficacy.
Brandt C, Seja P, Töllner K, Römermann K, Hampel P, Kalesse M, Kipper A, Feit PW, Lykke K, Toft-Bertelsen TL, Paavilainen P, Spoljaric I, Puskarjov M, MacAulay N, Kaila K, Löscher W.
Brandt C, et al.
Neuropharmacology. 2018 Dec;143:186-204. doi: 10.1016/j.neuropharm.2018.09.025. Epub 2018 Sep 21.
Neuropharmacology. 2018.
PMID: 30248303